CME: Contemporary approaches and emerging therapies for the management of respiratory syncytial virus in infants and young high-risk children
ACCREDITATION EXPIRED: October 15, 2025
Activity Description / Statement of Need:
In this online, self-learning activity:
Respiratory syncytial virus (RSV) is a highly contagious pathogen belonging to the Pneumoviridae family that circulates seasonally with other respiratory viruses. The majority of the population is exposed to RSV, but children under the age of two years and older adults are at the greatest risk of significant morbidity and mortality. RSV infections are responsible for approximately 60-80% of pediatric bronchiolitis and 40% of pediatric pneumonia cases and are a major cause of global hospitalization and mortality. Almost 70% of children are exposed to RSV during their first year of life, and 90% are exposed within their first two years, resulting in an estimated 427,000 emergency department visits and 1.6 million pediatrician visits annually.
Target Audience:
HCPs including: Obstetricians, pediatricians, and family medicine physicians; physician assistants, nurse practitioners, pharmacists specializing in pediatrics; and any other HCPs involved or interested in the management of RSV in infants and high-risk children.
Commercial Support Disclosure: This program is supported by an educational grant from Merck Sharp & Dohme.
This activity is free of charge.
Release Date: October 15, 2023 -- Expiration Date: October 15, 2025
Faculty: Priya Soni, MD
Agenda
|
Faculty introduction and disclosures |
|
Introductory content and review of RSV · Epidemiology and risk factors · Transmission and pathophysiology · Clinical manifestations, recognition, and diagnosis |
|
Prevention - Currently available: anti-RSV mAb o Identifying candidates and special populations: immunocompromise, pulmonary complications, congenital heart disease, neuromuscular disorders o Efficacy and safety o Extent of prematurity o Presence or absence of bronchopulmonary dysplasia o Managing breakthrough infections - Emerging: o Vaccines o mAbs - Treatment of RSV bronchiolitis o Supportive care: oxygen in cases of desaturation, fluid replacement, nasal decongestion o Special populations: stem cell, solid organ transplant recipients - Patient case(s) |
|
Summary, conclusion, and best practice recap |
Learning Objectives
By the end of the session the participant will be able to:
- Describe the epidemiology, history, transmission, clinical manifestations, and diagnosis of RSV infection in infants and high-risk children.
- Identify pediatric patients who are the greatest risk of experiencing morbidity and mortality associated with RSV.
- Summarize the currently available and emerging preventative therapeutic options for management of RSV infection.
- Review currently available therapeutic options for management of RSV infections in infants and high-risk children.
- Formulate preventative or treatment strategies for pediatric patients at high risk for morbidity and mortality associated with RSV disease or those with active infection.
Accreditation
ACCME Activity #202567356
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosures of Faculty: Priya R. Soni, MD, Assistant Professor, Pediatric Infectious Diseases, Cedars-Sinai, has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL discuss off-label uses of a commercial product.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Merck Sharp & Dohme.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Preventing and mitigating skeletal-related events in breast cancer